Sanofi (FRA:SNW)
Market Cap | 96.74B |
Revenue (ttm) | 45.74B |
Net Income (ttm) | 9.13B |
Shares Out | n/a |
EPS (ttm) | 7.36 |
PE Ratio | 10.60 |
Forward PE | 9.76 |
Dividend | 3.92 (4.89%) |
Ex-Dividend Date | May 12, 2025 |
Volume | 3,481 |
Average Volume | 2,183 |
Open | 79.38 |
Previous Close | 79.41 |
Day's Range | 79.27 - 79.92 |
52-Week Range | 76.92 - 110.02 |
Beta | n/a |
RSI | 40.13 |
Earnings Date | Oct 24, 2025 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Sanofi Commits $625 Mln To Expand Venture Fund
(RTTNews) - Sanofi Winthrop Industrie SA, Sanofi SA (SAN.PA, SNY, SNYNF), a French pharmaceutical and healthcare company, on Wednesday said it has made an additional $625 million multi-year capital co...

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare di...

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare di...

Press release: Availability of the Q3 2025 Aide mémoire
Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Third q...

Press release: Availability of the Q3 2025 Aide mémoire
Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: Third q...
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript
Sanofi (NEOE:SAN:CA) Bank of America Global Healthcare Conference 2025 September 23, 2025 4:50 AM EDTCompany ParticipantsPaul Hudson - CEO &...
FDA Grants Fast Track Status To Sanofi's Gene Therapy For Non-Congenital DM1
(RTTNews) - The U.S. Food and Drug Administration has granted Fast Track designation to SAR446268, Sanofi's (SNY,SNYNF,SAN.PA) investigational one-time AAV gene therapy targeting non-congenital forms ...

Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex...

Press Release: Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex...
Press Release: Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
Sanofi's SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK ex...

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision
Sanofi's tolebrutinib review for non-relapsing ... Full story available on Benzinga.com
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.
Sanofi (SNY) Advances with Dupixent for Skin Condition in EU
Sanofi (SNY) Advances with Dupixent for Skin Condition in EU
Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recomm...

Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three...
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...

Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...
Irelands pharma sector is world class, but why dont we have a Novo Nordisk to take our success to the next level?
Denmark has Novo Nordisk, France has Sanofi, Switzerland boasts both Roche and Novartis, while Germany has Bayer. Its a somewhat troubled relationship, but Britain has AstraZeneca.
Sanofi's Brivekimig Shows Efficacy In Biologic-Naïve HS Patients In Phase 2a Study
(RTTNews) - Sanofi (SNY) announced promising new data from its HS-OBTAIN phase 2a study, highlighting the efficacy of brivekimig in treating biologic-naïve patients with moderate-to-severe hidradeniti...
Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary e...

Press Release: EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
EADV: Sanofi's brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary e...

How the UK fell out with big pharma
The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a 1 billion facility in London and pulled its research activities altogether. Now Eli Lilly, San...

Britain is ‘a terrible place’ to sell medicines, says drug firm executive
Sanofi’s market access chief urges ministers to come up with a roadmap to raise spending on new treatments Business live – latest updates A senior pharmaceuticals executive has called on the governmen...
Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t...

Press Release: Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
Sanofi's SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate t...